Activity of telithromycin against 26 quinolone-resistant pneumococci with known quinolone-resistance mechanisms  by Nilgai, K. et al.
Activity of telithromycin against 26 quinolone-resistant pneumococci with
known quinolone-resistance mechanisms
K. Nagai1, D. Hoellman1, T. Davies1, M. Jacobs2 and P. Appelbaum1
1Department of Pathology, Hershey Medical Center, Hershey, PA 17033 and 2Department of Pathology, Case Western
Reserve University, Cleveland, OH 44106, USA
Tel: þ1 717 531 5113 Fax: þ1 717 531 7953 E-mail: pappelbaum@psu.edu
NCCLS agar dilution was used to test activity of telithromycin compared to clarithromycin, penicillin
G, ciprofloxacin, levofloxacin, sparfloxacin and moxifloxacin against 26 pneumococci with defined quinolone
resistance (type II topoisomerase and efflux) mechanisms. Thirteen strains were penicillin susceptible, six
intermediate and seven resistant. Clarithromycin resistance (mef and/or erm) was seen in eight strains.
Ciprofloxacin MICs (mg/L) were 8–64 compared to 1–32 (levofloxacin), 0.5 32 (sparfloxacin) and
0.125–4 (moxifloxacin). Telithromycin MIC50 and MIC90 values (mg/L) were 0.016 and 0.25, with only
one strain having an MIC of 2 mg/L.
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The incidence of pneumococci resistant to penicillin G and
other b-lactam and non-b-lactam compounds has increased at a
rapid rate, in the USA and elsewhere. Major foci of infections
currently include South Africa, Spain, Central and Eastern
Europe, and parts of Asia [1–4]. In the USA a recent survey
has shown that 50.4% of 1476 clinically significant pneumo-
coccal isolates were not susceptible to penicillin; overall macro-
lide resistance was 33%, with 5% of penicillin-susceptible strains,
37% of penicillin-intermediate strains and 66% of penicillin-
resistant strains being macrolide resistant. No quinolone-resistant
strains were isolated [5]. Macrolide-resistance rates are higher in
southern Europe and Asia [4]. The therapeutic problem of
drug-resistant pneumococci is complicated by the ability of
resistant clones to spread from country to country, and from
continent to continent [6,7].
The incidence of quinolone-resistant pneumococci is cur-
rently very low in most countries [8,9]. However, recent reports
from Hong Kong [10], Canada [11] and Spain [12] have
documented a worrying increase in pneumococci with
increased minimal inhibitory concentrations (MICs) for qui-
nolones, especially in strains with increased penicillin MICs.
Effective drugs are required in order to treat the latter organism
group.
Telithromycin is a ketolide with a low MICs against pneu-
mococci, irrespective of their macrolide MICs [13]. This study
examined the telithromycin MICs of 26 pneumococcal strains
with known quinolone-resistance mechanisms.
Twenty-six quinolone-resistant strains with ciprofloxacin
MICs 8 mg/L [8] were obtained from the Alexander Project
collection via D. Felmingham and R. Gru¨neberg, London, UK.
Although the National Committee for Clinical Laboratory
Standards (NCCLS) has not defined streptococcal (or pneu-
mococcal) breakpoints for ciprofloxacin, a ciprofloxacin MIC
8.0 mg/L was considered highly resistant for the purposes of
these studies [8,9]. Additionally, those strains which were not
susceptible to ciprofloxacin were tested for mutations in parC,
gyrA, parE and gyrB and for efflux. Pneumococcal serotyping of
these strains was not performed.
Microbroth dilution MICs were performed according to
NCCLS recommendations [14] using cation-adjusted Muel-
ler–Hinton broth with 5% lysed defibrinated horse blood.
Standard quality control strains, including Streptococcus pneumo-
niae ATCC 49619, were included in each run.
Macrolide-resistance mechanisms were determined by the
polymerase chain reaction method (PCR) [15]. PCR was used
to amplify parC, parE, gyrA and gyrB using primers and cycling
conditions described by Pan et al. [16]. Template DNA for PCR
was prepared using Prep-A-Gene kit (Bio-Rad, Hercules, CA)
as recommended by the manufacturer. After amplification PCR
products were purified from excess primers and nucleotides
using the QIAquick PCR Purification kit as recommended by
the manufacturer (Qiagen, Valencia, CA) and sequenced
directly using the Applied Bio-systems Model 373A DNA
sequencer. Genes were sequenced twice in the forward direc-
tion and once in the reverse direction on products of indepen-
dent PCR reactions [8,9,16].
MICs of all quinolones were determined in the presence and
absence of 10 mg/L of reserpine (Sigma Chemicals, St. Louis,
MO, USA) as described previously. Tests were repeated three
times. Strains showing a more than four-fold decrease in MIC
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with reserpine were considered to have an efflux mechanism
[8,9,17].
MICs are presented in Table 1. Against 26 strains with
ciprofloxacin MICs 8 mg/L, moxifloxacin had the lowest
MICs (0.125–4.0 mg/L), compared with MICs ranging
between 0.5 and >32.0 mg/L for sparfloxacin, 1.0–32.0 mg/L
for levofloxacin and 8.0–64.0 mg/L for ciprofloxacin. Clari-
thromycin resistance (MICs 1.0 mg/L) was seen in eight
strains; five of these had mefE (MIC 2 mg/L), two strains had
ermB (MIC 8 to >32 mg/L) and one strain had both mefE and
ermB (MIC >32 mg/L). Thirteen strains were penicillin sus-
ceptible (MICs 0.06 mg/L), six strains were penicillin inter-
mediate (MICs 0.125–1.0 mg/L) and seven were penicillin
resistant (MICs 2.0–4.0 mg/L). Telithromycin MICs ranged
from 0.002–2.0 mg/L, with an MIC50 of 0.016 mg/L and
an MIC90 of 0.25 mg/L.
Enzymatic mechanisms of quinolone resistance are presented
in Table 1. As can be seen, increased quinolone MICs were
associated with mutations in the quinolone-resistance-deter-
mining region (QRDR) of ParC, GyrA, ParE and/or GyrB.
Twenty-five strains had mutations in ParC at S79-F or Y, D83-
N or G, R95-C, or K137-N, with 10 having double mutations
in ParC. Twenty-one strains had mutations in GyrA at S81-A,
C, F, or Y; E85-K; or S114-G, with one having a double
mutation in GyrA. Nineteen strains had single mutations in
ParE at D435-N or I460-V. Only one strain had a mutation in
Table1 Minimal inhibitory concentrations (MICs) of telithromycin and quinolones and topoisomerase IImutations in the 26 quinolone-resistant strains
MIC (mg/L) Mutation in QRDRof
Strain Pen G Clarith Telith Cipro Levo Spar Moxi ParC ParE GyrA GyrB
1 2.0 2.0 0.03 8.0 8.0 4.0 2.0 S79-F
K137-N
I460-V S81-F None
2 0.016 0.03 0.016 8.0 2.0 0.5 0.25 S79-Y I460-V None None
3 1.0 0.03 0.016 16.0 8.0 1.0 2.0 D83-N I460-V S81-F None
4 2.0 0.03 0.004 16.0 8.0 1.0 2.0 S79-F
K137-N
I460-V S81-F None
5 0.016 0.03 0.002 8.0 8.0 1.0 1.0 R95-C D435-N S81-F None
6 1.0 8.0 0.004 32.0 32.0 8.0 4.0 S79-Y
K137-N
I460-V E85-K None
7 0.03 0.06 0.016 8.0 2.0 1.0 0.25 None I460-V None None
8 0.016 0.03 0.03 8.0 1.0 1.0 0.125 S79-Y None None None
9 0.06 2.0 0.5 16.0 4.0 2.0 0.25 S79-Y None None None
10 0.016 0.03 0.016 16.0 8.0 4.0 1.0 S79-F I460-V S81-C None
11 4.0 2.0 0.06 16.0 4.0 4.0 0.25 S79-F I460-V S81-F None
12 2.0 0.03 0.016 8.0 4.0 8.0 0.25 S79-F
K137-N
I460-V None E474-K
13 1.0 0.03 0.016 16.0 8.0 8.0 2.0 S79-F
K137-N
I460-V S81-F None
14 2.0 0.03 0.008 16.0 8.0 8.0 1.0 S79-F
K137-N
I460-V S81-F None
15 0.016 0.03 0.016 64.0 16.0 8.0 2.0 S79-F I460-V S81-F None
16 0.016 >32.0 2.0 32.0 8.0 8.0 1.0 D83-N None S81-F None
17 0.016 0.03 0.004 64.0 16.0 8.0 2.0 S79-F I460-V S81-F None
18 0.125 0.03 0.016 32.0 16.0 8.0 4.0 S79-F I460-V S81-F None
19 0.016 0.03 0.004 32.0 16.0 8.0 2.0 S79-F
K137-N
I460-V S81-F None
20 0.016 0.03 0.016 64.0 16.0 8.0 2.0 S79-F I460-V S81-Y None
21 1.0 0.03 0.002 64.0 8.0 8.0 1.0 S79-Y None S81-A None
22 1.0 0.03 0.002 16.0 8.0 16.0 1.0 S79-F
K137-N
I460-V S81-F None
23 2.0 2.0 0.25 32.0 8.0 16.0 2.0 D83-G
N91-D
None S81-F None
24 0.016 0.03 0.016 64.0 16.0 >32.0 2.0 S79-F None S81-Y None
25 0.016 >32.0 0.06 32.0 16.0 >32.0 2.0 S79-Y I460-V S81-F None
26 4.0 2.0 0.125 64.0 16.0 >32.0 2.0 D83-G
N91-D
None S81-F
S114-G
None
None
 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 7, 697–711
704 Clinical Microbiology and Infection, Volume 12 Number 12, December 2001
GyrB at E474-K. Nineteen strains had a total of three or four
mutations in the QRDRs of ParC, GyrA, ParE and GyrB
(Table 1).
In the presence of reserpine 12 strains had lower ciprofloxacin
MICs (4–16-fold); two strains had lower levofloxacin MICs
(four-fold); one had lower moxifloxacin MICs (four-fold).
Three strains had lower MICs to two agents and one strain
to three agents in the presence of reserpine.
Against 26 strains with significantly raised quinolone MICs
and with known quinolone-resistance mechanisms, sometimes
comprising more than four mutations, telithromycin yielded
low MICs for all except one strain (2.0 mg/L). The latter strain
carried an ermB gene.
With the introduction and widespread use of broad-spectrum
quinolones, such as gatifloxacin, moxifloxacin and gemiflox-
acin, there is a likelihood that quinolone resistance will become
more widespread in pneumococci. Although many quinolone-
resistant strains were penicillin susceptible, multiple resistance to
penicillin G, clarithromycin and quinolones was sometimes
seen in our study; this phenomenon has also been reported
by other workers [10–12]. The results of this study indicate that
telithromycin was still active in vitro against the great majority of
these strains, and may reflect a therapeutic alternative if these
strains become more prevalent.
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